Market Place
Sourcing Support
TransCode Therapeutics Names Janicot Senior Development Officer
17 Nov 2025 //
PR NEWSWIRE
TransCode Therapeutics Open Letter to Shareholders
12 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Nasdaq to Regain Compliance
05 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24 Jul 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 Jul 2024 //
GLOBENEWSWIRE
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22 Jul 2024 //
GLOBENEWSWIRE
Nasdaq Says TransCode Regained Listing Compliance Requirements
10 Jun 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Open Letter to Shareholders
13 May 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 Apr 2024 //
GLOBENEWSWIRE
TransCode Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 Mar 2024 //
GLOBENEWSWIRE
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
06 Mar 2024 //
GLOBENEWSWIRE
TransCode Reports Publication of Patent Covering RIG-I Agonist Immunotherapeutic
20 Feb 2024 //
GLOBENEWSWIRE
Nasdaq Determines TransCode Compliance with Stockholders™ Equity Requirement
31 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics and Debiopharm Announce Collaboration
29 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
22 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
18 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Reports Further Restructuring
12 Jan 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
11 Jan 2024 //
GLOBENEWSWIRE
TransCode Publishes Open Letter Outlining Company™s Progress and Objectives
04 Jan 2024 //
GLOBENEWSWIRE
TransCode To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
05 Dec 2023 //
GLOBENEWSWIRE
TransCode Announces Closing of $1.2M Direct Offering of Common Stock
04 Dec 2023 //
GLOBENEWSWIRE
TransCode Announces $1.2 Million Registered Direct Offering of Common Stock
30 Nov 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Reports Third Quarter 2023 Results
14 Nov 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Withdraws Public Offering
30 Oct 2023 //
GLOBENEWSWIRE
Nasdaq Panel Grants TransCode Extension for Continued Listing on The Nasdaq
27 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Public Offering of Common Stock
26 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Preliminary Clinical Results in TTX-MC138
24 Oct 2023 //
GLOBENEWSWIRE
TransCode Reports Successful Treatment of Preclinical Melanoma Tumors
16 Oct 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
28 Sep 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
25 Sep 2023 //
GLOBENEWSWIRE
TransCode Reports Second Quarter 2023 Results; Provides Business Update
14 Aug 2023 //
GLOBENEWSWIRE
TransCode Therapeutics CEO Letter to Shareholders
05 Jul 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Closing of $7 Million Public Offering
09 Jun 2023 //
PRESS RELEASE
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
06 Jun 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
22 May 2023 //
GLOBENEWSWIRE
TransCode Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
27 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
26 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics to present at AACR Annual Meeting 2023
06 Apr 2023 //
GLOBENEWSWIRE
TransCode Announces Termination of Announced Sale of Series A Preferred Stock
04 Apr 2023 //
GLOBENEWSWIRE
TransCode Announces Agreement with Triton Funds for Sale of Preferred Stock
03 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Reports 2022 Results; Provides Business Update
31 Mar 2023 //
GLOBENEWSWIRE
TransCode Announces Closing of $1.5M Registered Direct Offering of Common Stock
17 Feb 2023 //
GLOBENEWSWIRE
TransCode Announces $1.5M Registered Direct Offering of Common Stock
16 Feb 2023 //
GLOBENEWSWIRE
Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today
01 Feb 2023 //
FINANCE YAHOO
TransCode Announces FDA Authorization to Proceed with First-In-Human Trial
29 Dec 2022 //
GLOBENEWSWIRE
Penny stock pulls back on offering its shares amid ‘current market conditions’
07 Dec 2022 //
ENDPTS
TransCode Therapeutics Announces Withdrawal of Registration Statement
06 Dec 2022 //
GLOBENEWSWIRE
TransCode Announces eIND Submission to US FDA for Planned First-in-Human Trial
30 Nov 2022 //
GLOBENEWSWIRE
TransCode Therapeutics Reports 3Q 2022 Results; Provides Business Update
14 Nov 2022 //
GLOBENEWSWIRE
TransCode Reports +Ve Preclinical Results with its Immunotherapy, TTX-siPDL1
09 Nov 2022 //
GLOBENEWSWIRE
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
07 Nov 2022 //
GLOBENEWSWIRE
Community, NeuroBo healthcare gainers; Taysha, TransCode lead losers` pack
27 Oct 2022 //
SEEKING ALPHA
TransCode Reports Positive Results with its Lead Candidate, TTX-MC138
26 Oct 2022 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Publication of Feline Case Study in Oncology
13 Oct 2022 //
GLOBENEWSWIRE
TransCode Therapeutics to Participate at the Chardan 6th Annual
27 Sep 2022 //
GLOBENEWSWIRE
TransCode Therapeutics Reports Second Quarter 2022 Results
15 Aug 2022 //
GLOBENEWSWIRE
TransCode Therapeutics and MD Anderson Announce Strategic Alliance
02 Aug 2022 //
GLOBENEWSWIRE
TransCode Therapeutics to Participate at BIO International Convention
09 Jun 2022 //
GLOBENEWSWIRE
TransCode Therapeutics Receives NIH Notice of Award
01 Jun 2022 //
GLOBENEWSWIRE
TransCode Tx To Participate at H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
